drugset / Trial / NCT06693674
Effect of Sacubitril-Valsartan on Cardiac Structure and Function
Phase 3
Recruiting
45 enrolled
Mayo Clinic
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to compare changes in cardiac structure and function, biomarkers, and patient reported outcomes between adults with congenital heart disease (ACHD) randomized to angiotensin receptor-neprilysin inhibitor (ARNI) therapy vs placebo.
Timeline
- Start
- 2025-02-03
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LCZ696 | Unknown | 24 mg | Oral |
| Subject | LCZ696 | Unknown | 49 mg | Oral |
| Subject | LCZ696 | Unknown | 97 mg | Oral |